Supramolecular salicylic acid sustained-release agent as well as preparation method and application thereof

By preparing a supramolecular salicylic acid sustained-release agent, the problems of salicylic acid solubility and skin irritation in cosmetics were solved, achieving a long-term controlled-release and low-irritation acne-removing effect.

CN118948863AInactive Publication Date: 2024-11-15RUMEI (GUANGZHOU) BIOENGINEERING CO LTD

Patent Information

Application Number
CN202411028380.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing salicylic acid drugs have issues with solubility and skin irritation in the cosmetics field, which affects their effectiveness in treating skin diseases.

Method used

A supramolecular salicylic acid sustained-release agent is prepared by compounding salicylic acid and polyethylene glycol/polypropylene glycol-17/6 copolymer, and then dissolving and gelling it through stirring and heating to form a water-soluble sustained-release agent without organic solvents.

Benefits of technology

It achieves controlled and sustained release of salicylic acid, has good biocompatibility, low skin irritation, reduces stinging, redness and peeling, and improves acne treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948863A_ABST
    Figure CN118948863A_ABST
Patent Text Reader

Abstract

The invention discloses a supramolecular salicylic acid sustained-release agent as well as a preparation method and application thereof, and relates to the field of supramolecules. The supramolecular salicylic acid sustained-release agent is prepared from the following components in percentage by mass: 0.5 to 30 percent of salicylic acid and 0.5 to 15 percent of polyethylene glycol / polypropylene glycol-17 / 6 copolymer. According to the supramolecular salicylic acid sustained-release agent provided by the embodiment of the invention, salicylic acid and a polyethylene glycol / polypropylene glycol-17 / 6 copolymer are compounded. On one hand, the salicylic acid can be dissolved in water under the condition that no organic solvent is used, so that the salicylic acid sustained-release agent has the controlled-release and sustained-release capacity, and the controlled-release and sustained-release effect can be continuously exerted for a long time; on the other hand, through the compounding effect of salicylic acid and polyethylene glycol / polypropylene glycol-17 / 6, the salicylic acid supramolecular sustained-release agent can have good biocompatibility, relatively high water dispersibility, no toxicity and relatively low skin irritation; meanwhile, in a clinical test, the salicylic acid supramolecular sustained-release agent is small in pricking feeling, less in redness, less in desquamation, free of itching and excellent in acne removing effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the supramolecular field, and in particular to a supramolecular salicylic acid sustained-release agent and a preparation method and application thereof. Background Art

[0002] Salicylic acid, also known as salicylic acid, is a common phenolic compound in plants. The Compendium of Materia Medica records that willow leaves have anti-inflammatory effects. The analgesic effect of willow leaves was also recorded in ancient Greece. This shows that some components in willow leaves have anti-inflammatory and analgesic effects. In 1828, German scientist John Buchner extracted the active ingredient from willow bark and named it salicin. After further purification, a compound with stronger active efficacy, salicylic acid, was obtained. Salicylic acid has good anti-inflammatory and analgesic effects, but there are side effects such as nausea, vomiting, and even gastric ulcers and acidosis. In 1893, German chemist Hofman chemically reacted salicylic acid and acetic anhydride to synthesize acetylsalicylic acid, i.e. aspirin. The acetyl group can neutralize the strongness of salicylic acid, can more effectively protect the gastric mucosa, and the overall performance of the drug is significantly improved. Salicylic acid drugs are widely used in clinical practice for their good antipyretic, analgesic, anti-inflammatory, anti-tuberculosis, anti-rheumatic and rheumatoid effects.

[0003] However, most salicylic acid drugs are insoluble in water, so traditional salicylic acid preparations use alcohol or other organic solvents to dissolve salicylic acid, but this will irritate the skin, greatly limiting its drug absorption and clinical application effects. In order to solve the application problem of salicylic acid in the field of cosmetics, researchers have done a lot of work to optimize salicylic acid, including chemical modification, liposomeization, microencapsulation, and supramolecularization of salicylic acid. Among them, supramolecularization of salicylic acid shows superior performance. Supramolecular salicylic acid has the following characteristics: no ethanol, no addition of strong alkali neutralizer, stable properties, controlled sustained release, heat resistance, high transdermal efficiency, good local tolerance and other advantages. Supramolecular salicylic acid is widely used in the treatment of various skin diseases such as acne, rosacea, and seborrheic dermatitis. For example, patent CN201510626990.4 discloses a water-soluble supramolecular salicylic acid gel technology. The hydrogel is composed of a mixed solution of ethanol and propylene glycol in which multiple active ingredients such as α-cyclodextrin, low molecular weight fish collagen, starch nanocrystal poloxamer, etc. are dissolved. The various ingredients have a synergistic effect and can effectively treat acne. However, the presence of ethanol solution cannot avoid irritation to the skin. Patent CN201910742157.4 discloses a supramolecular salicylic acid preparation and a preparation method thereof. A mixed solution of isohexanediol and isopentyl glycol is used to disperse polyquaternary ammonium salt and montmorillonite to prepare a supramolecular salicylic acid preparation with good water dispersibility and low irritation. Although salicylic acid drugs have been effectively improved in terms of solubility and skin irritation, the efficacy of salicylic acid for skin diseases such as hemorrhoids has been greatly reduced. Summary of the invention

[0004] In order to solve the above technical problems existing in the prior art, the present application provides a supramolecular salicylic acid sustained-release agent and a preparation method and application thereof.

[0005] In order to achieve the above purpose, the technical solution of the embodiment of the present application is:

[0006] The first aspect of the present application provides a supramolecular salicylic acid sustained-release agent, comprising the following components in mass fractions:

[0007] 0.5-30% salicylic acid, 0.5-15% polyethylene glycol / polypropylene glycol-17 / 6.

[0008] The second aspect of the present application provides a method for preparing the supramolecular salicylic acid sustained-release agent according to the first aspect, the preparation method comprising:

[0009] Add salicylic acid to water and heat to dissolve under stirring to form a salicylic acid solution;

[0010] The polyethylene glycol / polypropylene glycol-17 / 6 copolymer is added to the salicylic acid solution, heated to gel under stirring, and the supramolecular salicylic acid sustained-release agent is collected.

[0011] In combination with the second aspect, preferably, the mass fraction of salicylic acid is 0.5-30% salicylic acid.

[0012] In combination with the second aspect, preferably, the mass fraction of the polyethylene glycol / polypropylene glycol-17 / 6 copolymer is 0.5-15%.

[0013] In combination with the second aspect, preferably, the salicylic acid is added to water, and the amount of water added is 20 to 100 mL.

[0014] In combination with the second aspect, preferably, when the heating and dissolving under stirring is performed, the heating temperature is 50-80°C.

[0015] In combination with the second aspect, preferably, when the heating and dissolving under stirring is performed, the stirring speed is 350 to 800 rpm / min, and the stirring time is 6 to 12 hours.

[0016] In combination with the second aspect, preferably, when the heating gelation under stirring is performed, the heating temperature is 50-80°C.

[0017] In combination with the second aspect, preferably, when the heating gelation under stirring is performed, the stirring speed is 350 to 800 rpm / min, and the stirring time is 6 to 12 hours.

[0018] The third aspect of the present application provides a method for preparing a supramolecular salicylic acid sustained-release agent as described in the first aspect or a supramolecular salicylic acid sustained-release agent prepared by any method as described in the second aspect for use in clinical anti-acne cosmetics.

[0019] Compared with the prior art, the advantages or beneficial effects of the embodiments of the present application include at least:

[0020] The supramolecular salicylic acid sustained-release agent provided in the embodiment of the present application specifically compounds salicylic acid and polyethylene glycol / polypropylene glycol-17 / 6 copolymer. On the one hand, salicylic acid can be dissolved in water without using any organic solvent, so that the salicylic acid sustained-release agent has the ability of controlled release and can exert the controlled release and sustained effect for a long time; on the other hand, through the compounding of salicylic acid and polyethylene glycol / polypropylene glycol-17 / 6, the salicylic acid supramolecular sustained-release agent can have good biocompatibility, high water dispersibility, non-toxicity and low skin irritation; at the same time, the salicylic acid supramolecular sustained-release agent has less stinging, less redness, less desquamation, no itching and excellent acne removal effect in clinical trials.

[0021] The method for preparing the supramolecular salicylic acid sustained-release agent provided in the embodiment of the present application uses polyethylene glycol / polypropylene glycol-17 / 6 copolymer and salicylic acid as raw materials. Since the polyethylene glycol / polypropylene glycol-17 / 6 copolymer has a lot of hydroxyl groups, it can form a lot of hydrogen bonds with the carboxyl groups of salicylic acid, which is conducive to the dissolution of salicylic acid, so that salicylic acid and the polyethylene glycol / polypropylene glycol-17 / 6 copolymer can fully play a synergistic role, giving the prepared supramolecular salicylic acid sustained-release agent less stinging, less redness, less desquamation, no itching, and good acne removal effect in clinical trials. The prepared supramolecular salicylic acid sustained-release agent has good biocompatibility, high water dispersibility and low skin irritation. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 These are test effect diagrams of the supramolecular salicylic acid sustained-release agents prepared in Examples 1-6 and the common salicylic acid sustained-release agents prepared in Comparative Examples 1-4. DETAILED DESCRIPTION

[0023] In order to make the purpose, technical solutions and advantages of the present application clearer, the present application will be further described in detail below in conjunction with the accompanying drawings. The described embodiments should not be regarded as limiting the present application. All other embodiments obtained by ordinary technicians in the field without making creative work are within the scope of protection of this application.

[0024] In the following description, reference is made to "some embodiments", which describe a subset of all possible embodiments, but it is understood that "some embodiments" may be the same subset or different subsets of all possible embodiments, and may be combined with each other without conflict. Unless otherwise defined, all technical and scientific terms used in the embodiments of the present application have the same meaning as those commonly understood by those skilled in the art of the technical field of the embodiments of the present application. The terms used in the embodiments of the present application are only for the purpose of describing the embodiments of the present application and are not intended to limit the present application.

[0025] In the following description of this embodiment, the terms "include", "comprising", "having" and "containing" are all open terms, meaning including but not limited to.

[0026] It should be noted that all raw materials / reagents in the examples of the present application can be purchased on the market or prepared according to conventional methods well known to those skilled in the art; the term "and / or" in the examples of the present application is only used to describe the association relationship between associated objects, indicating that three relationships may exist, for example, A and / or B means the existence of A alone, B alone, and A and B at the same time, among which A and B can be singular or plural, and the character " / " generally indicates that the associated objects before and after are in an "or" relationship.

[0027] In the following description of this embodiment, the term "at least one" refers to one or more, and "plurality" refers to two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single items or plural items. For example, "at least one of a, b or c", or "at least one of a, b and c", can all represent: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, c can be single or multiple, respectively.

[0028] Those skilled in the art should understand that in the following description of the embodiments of the present application, the order of serial numbers does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.

[0029] The terms used in the embodiments of the present application are only for the purpose of describing specific embodiments, and are not intended to limit the present application. The singular forms "a", "an" and "the" used in the embodiments of the present application and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.

[0030] Those skilled in the art will appreciate that the numerical ranges in the examples of the present application are to be understood as also specifically disclosing each intermediate value between the upper and lower limits of the range. Each smaller range between the intermediate values ​​in any stated value and stated range and any other stated value or intermediate value in the range is also included in the present application. The upper and lower limits of these smaller ranges may be independently included or excluded in the scope.

[0031] Unless otherwise stated, the technical / scientific terms used herein have the same meanings as those generally understood by those skilled in the art in the field described in the present application. Although the present application only describes preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the embodiments or test cases of the present application. All documents mentioned in this specification are generally incorporated by reference to disclose and describe the methods and / or materials related to the documents. In the event of a conflict with any incorporated document, the content of the present application shall prevail.

[0032] It should be noted that all raw materials and / or reagents in the examples of the present application are purchased on the market or prepared according to conventional methods well known to those skilled in the art.

[0033] In a first aspect, the present invention provides a supramolecular salicylic acid sustained-release agent, comprising the following components in mass fractions:

[0034] 0.5-30% salicylic acid, 0.5-15% polyethylene glycol / polypropylene glycol-17 / 6 copolymer.

[0035] The supramolecular salicylic acid sustained-release agent provided in the embodiment of the present application specifically compounds salicylic acid and polyethylene glycol / polypropylene glycol-17 / 6 copolymer. On the one hand, salicylic acid can be dissolved in water without using any organic solvent, so that the salicylic acid sustained-release agent has the ability of controlled release and can exert the controlled release and sustained effect for a long time; on the other hand, through the compounding of salicylic acid and polyethylene glycol / polypropylene glycol-17 / 6, the salicylic acid supramolecular sustained-release agent can have good biocompatibility, high water dispersibility, non-toxicity and low skin irritation; at the same time, the salicylic acid supramolecular sustained-release agent has less stinging, less redness, less desquamation, no itching and excellent acne removal effect in clinical trials.

[0036] In a second aspect, the present application provides a method for preparing the supramolecular salicylic acid sustained-release agent according to the first aspect, the preparation method comprising:

[0037] S1: adding salicylic acid into water, heating and dissolving under stirring to form a salicylic acid solution;

[0038] S2: adding polyethylene glycol / polypropylene glycol-17 / 6 copolymer to the salicylic acid solution, heating and gelling under stirring, and collecting supramolecular salicylic acid sustained-release agent.

[0039] In the preparation method provided in the present application, there is no limitation on stirring and heating in S1. For example, salicylic acid can be directly added to water and heated under mechanical stirring to make it dissolve evenly. The present application preferably reacts salicylic acid at 50-80°C, 350-800rpm / min, and the stirring time is 6-12h to obtain a salicylic acid solution.

[0040] In the preparation method provided in the present application, there is no restriction on the mixing of polyethylene glycol / polypropylene glycol-17 / 6 copolymer and salicylic acid solution in S2. For example, the polyethylene glycol / polypropylene glycol-17 / 6 copolymer can be directly added to the salicylic acid solution, heated under mechanical stirring, and gelled to obtain a supramolecular salicylic acid sustained-release agent; the polyethylene glycol / polypropylene glycol-17 / 6 copolymer can also be slowly added dropwise to the salicylic acid solution, heated under mechanical stirring, and gelled to obtain a supramolecular salicylic acid sustained-release agent. The present application preferably adds the polyethylene glycol / polypropylene glycol-17 / 6 copolymer to the salicylic acid solution at 50-80°C and 350-800rpm / min, and the stirring time is 6-12h, and the reaction obtains a supramolecular salicylic acid sustained-release agent.

[0041] In a specific embodiment, the mass fraction of salicylic acid in the embodiment of the present application is preferably 0.5 to 30% salicylic acid.

[0042] It should be noted that the mass fraction of salicylic acid is based on the mass of salicylic acid / the mass of water. In the embodiment of the present application, the mass fraction of the salicylic acid is 0.5-30%. Wherein, the content of salicylic acid can be 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2wt%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30% or any one within the range.

[0043] When the mass fraction of salicylic acid is too high, it may cause greater irritation to the skin, easily causing adverse reactions such as redness, swelling, stinging, and peeling; at the same time, due to the unique permeability of salicylic acid, too high a concentration of salicylic acid will cause the skin to absorb too quickly, shortening the residence time of salicylic acid products on the skin surface, thereby affecting the sustained-release effect. When the mass fraction of salicylic acid is too low, it may not achieve the expected skin care effects, such as cleaning pores and removing dead skin cells.

[0044] In a specific embodiment, the mass fraction of the polyethylene glycol / polypropylene glycol-17 / 6 copolymer in the embodiment of the present application is preferably 0.5 to 15%.

[0045] It should be noted that the mass fraction of polyethylene glycol / polypropylene glycol-17 / 6 copolymer is based on the mass of polyethylene glycol / polypropylene glycol-17 / 6 copolymer / the mass of water. In the embodiment of the present application, the mass fraction of the polyethylene glycol / polypropylene glycol-17 / 6 copolymer is 0.5-15%. Among them, the content of polyethylene glycol / polypropylene glycol-17 / 6 copolymer can be 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2wt%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15% or any one within the range.

[0046] Among them, when the mass fraction of polyethylene glycol / polypropylene glycol-17 / 6 copolymer is too high, the viscosity of the sustained-release agent may increase significantly, thereby affecting the fluidity of the product and the user experience. When the mass fraction of polyethylene glycol / polypropylene glycol-17 / 6 copolymer is too low, oily ingredients such as salicylic acid may not be fully emulsified to form a stable dispersion system, thereby affecting the stability and use effect of the sustained-release agent.

[0047] In a specific embodiment, when heating and dissolving under stirring is performed in the embodiments of the present application, the amount of water added is preferably 20 to 100 mL.

[0048] In the examples of the present application, the amount of water added is 20-100 mL. The content of the surfactant may be 20 mL, 30 mL, 40 mL, 50 mL, 60 mL, 70 mL, 80 mL, 90 mL, 100 mL or any one within the range.

[0049] In a specific embodiment, when heating and dissolving are performed under stirring in the embodiments of the present application, the heating temperature is preferably 50 to 80°C.

[0050] Among them, when the heating temperature is too high, the thermal degradation rate of salicylic acid will accelerate, resulting in more decomposition phenomena, and the generation of oligomers or polymers, thereby reducing the supramolecular effect of the salicylic acid sustained-release agent; when the heating temperature is too low, it may be easy to crystallize, which may affect the reaction and the formation of the product.

[0051] In a specific embodiment, when heating and dissolving under stirring is performed in the embodiments of the present application, the stirring speed is preferably 350 to 800 rpm / min, and the stirring time is preferably 6 to 12 hours.

[0052] Among them, when the stirring speed is too high, the decomposition reaction of salicylic acid will be accelerated, and unnecessary by-products such as phenol, carbon dioxide and water will be produced; when the stirring speed is too slow, salicylic acid may be unevenly dissolved in the solution, resulting in local concentrations that are too high or too low, which may affect the quality and use effect of the salicylic acid sustained-release agent.

[0053] In a specific embodiment, when the embodiment of the present application is heated and gelled under stirring, the heating temperature is preferably 50 to 80°C.

[0054] Among them, when the temperature is too high, the gel structure formed by PEG / PPG-17 / 6 copolymer and salicylic acid may be destroyed, causing it to lose its original three-dimensional network structure, affecting the water absorption performance, physical stability and mechanical strength of the gel; when the temperature is too low, the PEG / PPG-17 / 6 copolymer and salicylic acid may not be fully cross-linked to form a gel, affecting the formation effect and physical properties of the gel.

[0055] In a specific embodiment, when the embodiment of the present application performs heating gelation under stirring, the stirring speed is preferably 350 to 800 rpm / min, and the stirring time is 6 to 12 hours.

[0056] The method for preparing the supramolecular salicylic acid sustained-release agent provided in the embodiment of the present application uses polyethylene glycol / polypropylene glycol-17 / 6 copolymer and salicylic acid as raw materials. Since the polyethylene glycol / polypropylene glycol-17 / 6 copolymer has a lot of hydroxyl groups, it can form a lot of hydrogen bonds with the carboxyl groups of salicylic acid, which is conducive to the dissolution of salicylic acid, so that salicylic acid and the polyethylene glycol / polypropylene glycol-17 / 6 copolymer can fully play a synergistic role, giving the prepared supramolecular salicylic acid sustained-release agent less stinging, less redness, less desquamation, no itching, and good acne removal effect in clinical trials. The prepared supramolecular salicylic acid sustained-release agent has good biocompatibility, high water dispersibility and low skin irritation.

[0057] In a third aspect, the embodiments of the present application provide a supramolecular salicylic acid sustained-release agent described in the first aspect or a supramolecular salicylic acid sustained-release agent prepared by any method described in the second aspect for use in the preparation of clinical anti-acne cosmetics.

[0058] The technical method of the present application will be further described below in conjunction with specific embodiments.

[0059] Example 1

[0060] This embodiment 1 provides a method for preparing a supramolecular salicylic acid sustained-release agent 1, and the specific steps are as follows:

[0061] (1) Weigh 10% salicylic acid by mass and put it into a beaker containing 50 ml of water. Heat and stir the mixture at 60° C. and 400 rpm for 6 h to form a uniform and transparent salicylic acid solution.

[0062] (2) Weigh 5% by mass of polyethylene glycol / polypropylene glycol-17 / 6 copolymer and add it to the salicylic acid solution. Continue heating and stirring at 60° C. and 400 rpm for 6 h to make the sol-gel to form supramolecular salicylic acid sustained-release agent 1.

[0063] Example 2

[0064] The supramolecular salicylic acid sustained-release agent 2 was prepared according to the method of Example 1, except that the mass fraction of the polyethylene glycol / polypropylene glycol-17 / 6 copolymer was 10%.

[0065] Example 3

[0066] The supramolecular salicylic acid sustained-release agent 3 was prepared according to the method of Example 1, except that the mass fraction of the polyethylene glycol / polypropylene glycol-17 / 6 copolymer was 15%.

[0067] Example 4

[0068] The supramolecular salicylic acid sustained-release agent 4 was prepared according to the method of Example 1, except that the mass fraction of salicylic acid was 20%.

[0069] Example 5

[0070] The supramolecular salicylic acid sustained-release agent 5 was prepared according to the method of Example 1, except that the mass fraction of salicylic acid was 25%, and the mass fraction of polyethylene glycol / polypropylene glycol-17 / 6 copolymer was 15%.

[0071] Example 6

[0072] The supramolecular salicylic acid sustained-release agent 6 was prepared according to the method of Example 1, except that the mass fraction of salicylic acid was 30%, and the mass fraction of polyethylene glycol / polypropylene glycol-17 / 6 copolymer was 15%.

[0073] Comparative Example 1

[0074] Ordinary salicylic acid sustained-release agent 1 was prepared according to the method of Example 1, except that the added raw material was polyethylene glycol, and the mass fraction of polyethylene glycol was 30%.

[0075] Comparative Example 2

[0076] Ordinary salicylic acid sustained-release agent 2 was prepared according to the method of Example 1, except that the added raw material was polypropylene glycol, and the mass fraction of polypropylene glycol was 30%.

[0077] Comparative Example 3

[0078] Ordinary salicylic acid sustained-release agent 3 was prepared according to the method of Example 1, except that only 2% of salicylic acid was added.

[0079] Comparative Example 4

[0080] Ordinary salicylic acid sustained-release agent 4 was prepared according to the method of Example 1, except that only 5% salicylic acid was added.

[0081] In order to verify the beneficial effects of the supramolecular salicylic acid sustained-release agents 1-6 prepared in Examples 1-6 and the supramolecular preparations of the common salicylic acid sustained-release agents 1-4 prepared in Comparative Examples 1-4 and their derivatives, the following irritation test was conducted in accordance with the relevant requirements of human skin tests in the "Technical Specifications for Safety of Cosmetics" (2015 Edition):

[0082] 50 volunteers aged 18-60 who met the test requirements were selected as subjects. The supramolecular salicylic acid sustained-release agents of different contents in Examples 1-6 were evenly applied to the face by gently pressing and rubbing with the palm of the hand. After 24 hours, the skin reaction was observed according to the standards in Table 1 and the observation results were recorded. The test results are shown in Table 2.

[0083] Table 1 Grading scale for skin test reaction of supramolecular salicylic acid sustained-release agent

[0084] Degree of reaction Rating Skin reactions + 1 No response ++ 2 Mild reaction +++ 3 General reaction ++++ 4 Strong reaction +++++ 5 Very strong

[0085] Table 2 Test results of supramolecular salicylic acid sustained-release agent irritation test

[0086] Tingling sensation Redness Desquamation Itching Acne-removing effect Example 1 4.43 4.29 2.29 2.43 4.57 Example 2 2.71 2.86 1.71 1.43 4.00 Example 3 1.00 1.14 1.43 1.29 3.43 Example 4 4.57 3.57 2.71 1.71 4.86 Example 5 3.29 2.71 2.14 3.00 4.29 Example 6 1.43 1.29 1.86 2.57 3.71 Comparative Example 1 2.82 2.72 2.63 2.35 2.75 Comparative Example 2 2.15 2.35 2.26 3.01 2.15 Comparative Example 3 4.63 4.55 3.43 3.58 4.62 Comparative Example 4 4.35 4.28 3.05 3.14 4.88

[0087] Figure 1 These are test effect diagrams of the supramolecular salicylic acid sustained-release agents prepared in Examples 1-6 and the common salicylic acid sustained-release agents prepared in Comparative Examples 1-4.

[0088] From Table 2 and Figure 1 It can be seen that when the amount of polyethylene glycol / polypropylene glycol-17 / 6 copolymer added is the largest, that is, 15%, the supramolecular salicylic acid sustained-release agent prepared in Examples 3 and 6 of the present application has no adverse skin reaction to the human body, and only adding polyethylene glycol PEG or polypropylene glycol PPG has a greater adverse reaction to the human body than adding polyethylene glycol / polypropylene glycol-17 / 6 copolymer. Salicylic acid without adding polyethylene glycol / polypropylene glycol-17 / 6 copolymer has adverse skin reactions to the human body. This shows that after the supramolecular treatment of salicylic acid, high-concentration salicylic acid can avoid direct contact with the skin, significantly reduce its irritation, effectively avoid the discomfort such as stinging, redness, desquamation and itching that it may cause, and improve the acne-removing effect of salicylic acid.

[0089] The above is only a specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any person skilled in the art who is familiar with the present technical field can easily think of changes or substitutions within the technical scope disclosed in the present application, which should be included in the protection scope of the present application. Therefore, the protection scope of the present application should be based on the protection scope of the claims.

Claims

1. A supramolecular salicylic acid sustained-release agent, It is characterized in that The composition includes the following components by mass fraction: 0.5-30% salicylic acid, 0.5-15% polyethylene glycol / polypropylene glycol-17 / 6 copolymer.

2. A method for preparing the supramolecular salicylic acid sustained-release agent according to claim 1, It is characterized in that include: Add salicylic acid to water and heat to dissolve under stirring to form a salicylic acid solution; The polyethylene glycol / polypropylene glycol-17 / 6 copolymer is added to the salicylic acid solution, heated to gel under stirring, and the supramolecular salicylic acid sustained-release agent is collected.

3. The method for preparing the supramolecular salicylic acid sustained-release agent according to claim 2, It is characterized in that The mass fraction of the salicylic acid is 0.5-30% salicylic acid.

4. The method for preparing the supramolecular salicylic acid sustained-release agent according to claim 2, It is characterized in that The mass fraction of the polyethylene glycol / polypropylene glycol-17 / 6 copolymer is 0.5-15%.

5. The method for preparing the supramolecular salicylic acid sustained-release agent according to claim 2, It is characterized in that The salicylic acid is added into water, and the amount of water added is 20-100 mL.

6. The method for preparing the supramolecular salicylic acid sustained-release agent according to claim 2, It is characterized in that When the heating and dissolving is performed under stirring, the heating temperature is 50 to 80°C.

7. The method for preparing the supramolecular salicylic acid sustained-release agent according to claim 2, It is characterized in that When the heating and dissolving under stirring is performed, the stirring speed is 350 to 800 rpm / min, and the stirring time is 6 to 12 hours.

8. The method for preparing the supramolecular salicylic acid sustained-release agent according to claim 2, It is characterized in that When the heating gelation is carried out under stirring, the heating temperature is 50 to 80°C.

9. The method for preparing the supramolecular salicylic acid sustained-release agent according to claim 2, It is characterized in that When the heating gelation under stirring is performed, the stirring speed is 350 to 800 rpm / min and the stirring time is 6 to 12 hours.

10. The supramolecular salicylic acid sustained-release agent according to claim 1 or the supramolecular salicylic acid sustained-release agent prepared by the method according to any one of claims 2 to 9 is used in the preparation of clinical anti-acne cosmetics.

Citation Information

Patent Citations

  • Water-soluble supramolecular salicylic acid gel technology

    CN105147596A

  • Salicylic acid supramolecular preparation and preparation method thereof

    CN112386522A

  • Cosmetic composition and application thereof, product using cosmetic composition and preparation method of product

    CN110101649A

Cited By

  • Salicylic acid sustained-release system, application and cosmetics

    CN120732711A

  • Supramolecular composition with sebum response and temperature-sensitive functions and method for producing same

    CN122721359A